Bafna Pharmaceuticals Ltd vs Ind Swift Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 131.85 as of 05 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd is 0 as of March 2022 .The P/E Ratio of Ind-Swift Ltd is 0 as of March 2022 . The Market Cap of Bafna Pharmaceuticals Ltd is ₹ 0 crore as of March 2022 .The Market Cap of Ind-Swift Ltd is ₹ 60.61 crore as of March 2022 . The revenue of Bafna Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Ind-Swift Ltd for the Mar '25 is ₹ 426.19 crore as compare to the Dec '24 revenue of ₹ 122.96 crore. This represent the growth of 246.61% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Ltd for the Mar '25 is ₹ 278.4 crore as compare to the Dec '24 ebitda of ₹ 9.98 crore. This represent the growth of 2689% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The net profit of Ind-Swift Ltd changed from ₹ 28.24 crore to ₹ 256.6 crore over 4 quarters. This represents a CAGR of 808.64% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ind-Swift Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Ind-Swift Ltd

Ind-Swift Limited (ISL) is an India-based pharmaceutical company.
The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage.
The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables.
The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and null

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Ind-Swift Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 311 Cr while Market cap of Ind-Swift Ltd is 85 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Ind-Swift Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Ind-Swift Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Ind-Swift Ltd?

As of May 5, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹131.85. On the other hand, Ind-Swift Ltd stock price is INR ₹15.7.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Ind-Swift Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Ind-Swift Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.